Study design and participants
CORONAVIRUS INFECTION
We conducted a non-randomized, single-center, prospective observational cohort study. The study was performed between August 20, 2022 and February 1, 2023 within the facilities of the multidisciplinary City Clinical Hospital No. 52 (Moscow, Russian Federation) and the N.F. Gamaleya Research Institute of Epidemiology and Microbiology (Moscow, Russian Federation). The trial was conducted in accordance with the ethical principles derived from international guidelines, including the Declaration of Helsinki, and was approved by the local ethics committee (version 1.1 of 08.09.2022). The study was registered on We included adults (18 years or older) of both sexes according to the following inclusion and exclusion criteria. Inclusion criteria were: 1) confirmed diagnosis of a new mild or moderate COVID-19 coronavirus infection (